Photon iso-effective dose for cancer treatment with mixed field radiation based on dose-response assessment from human and an animal model: Clinical application to boron neutron capture therapy for head and neck cancer

GONZÁLEZ, S.J.; POZZI, E.C.C.; MONTI HUGHES, A.; PROVENZANO, L.; KOIVUNORO, H.; CARANDO, D.G.; THORP, S.I.; CASAL, M.R.; BORTOLUSSI, S.; TRIVILLIN, V.A.; GARABALINO, M.A.; CUROTTO, P.; HEBER, E.M.; SANTA CRUZ, G.A.; KANKAANRANTA, L.; JOENSUU, H.; SCHWINT, A.E.

PHYSICS IN MEDICINE AND BIOLOGY

IOP PUBLISHING LTD

Año: 2017 vol. 62 p. 7938 - 7958

0031-9155

Boron neutron capture therapy (BNCT) is a treatment modality that combines different radiation qualities. Since the severity of biological damage following irradiation depends on the radiation type, a quantity different from absorbed dose is required to explain the effects observed in the clinical BNCT in terms of outcome compared with conventional photon radiation therapy. A new approach for calculating photon iso-effective doses in BNCT was introduced previously. The present work extends this model to include information from dose-response assessments in animal models and humans. Parameters of the model were determined for tumour and precancerous tissue using dose-response curves obtained from BNCT and photon studies performed in the hamster cheek pouch in vivo models of oral cancer and/or pre-cancer, and from head and neck cancer radiotherapy data with photons. To this end, suitable expressions of the dose-limiting Normal Tissue Complication and Tumour Control Probabilities for the reference radiation and for the mixed field BNCT radiation were developed. Pearson´s correlation coefficients and p-values showed that TCP and NTCP models agreed with experimental data (with r > 0.87 and p-values >0.57). The photon iso-effective dose model was applied retrospectively to evaluate the dosimetry in tumours and mucosa for head and neck cancer patients treated with BNCT in Finland. Photon iso-effective doses in tumour were lower than those obtained with the standard RBE-weighted model (between 10% to 45%). The results also suggested that the probabilities of tumour control derived from photon iso-effective doses are more adequate to explain the clinical responses than those obtained with the RBE-weighted values. The dosimetry in the mucosa revealed that the photon iso-effective doses were about 30% to 50% higher than the corresponding RBE-weighted values. While the RBE-weighted doses are unable to predict mucosa toxicity, predictions based on the proposed model are compatible with the observed clinical outcome. The extension of the photon iso-effective dose model has allowed, for the first time, the determination of the photon iso-effective dose for unacceptable complications in the dose-limiting normal tissue. Finally, the formalism developed in this work to compute photon-equivalent doses can be applied to other therapies that combine mixed radiation fields, such as hadron therapy.